"Glatiramer Acetate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A random polymer of L-ALANINE, L-GLUTAMIC ACID, L-LYSINE, and L-TYROSINE that structurally resembles MYELIN BASIC PROTEIN. It is used in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS.
| Descriptor ID |
D000068717
|
| MeSH Number(s) |
D12.644.219
|
| Concept/Terms |
TV 5010- TV 5010
- 5010, TV
- TV5010
- TV-5010
|
Below are MeSH descriptors whose meaning is more general than "Glatiramer Acetate".
Below are MeSH descriptors whose meaning is more specific than "Glatiramer Acetate".
This graph shows the total number of publications written about "Glatiramer Acetate" by people in this website by year, and whether "Glatiramer Acetate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 2 | 3 | 5 |
| 2018 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Glatiramer Acetate" by people in Profiles.
-
Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era. Adv Ther. 2021 07; 38(7):3550-3588.
-
COVID-19 will change MS care forever - No. Mult Scler. 2020 09; 26(10):1149-1151.
-
COVID-19 in MS: Initial observations from the Pacific Northwest. Neurol Neuroimmunol Neuroinflamm. 2020 09 03; 7(5).
-
Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations. Mult Scler Relat Disord. 2020 08; 43:102224.
-
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020 Aug; 43:102195.
-
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Mult Scler Relat Disord. 2020 Aug; 43:102174.
-
Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases. Mult Scler Relat Disord. 2018 Oct; 25:95-98.
-
Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis. Mult Scler Relat Disord. 2018 04; 21:117-119.
-
The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria. Sci Rep. 2017 Nov 15; 7(1):15653.
-
Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry. 2017 08; 88(8):639-647.